Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986442

Next Previous
Drug Profile

BMS 986442

Alternative Names: AGEN-1777; anti-TIGIT bispecific antibody; BMS-986-442

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer Agenus; Bristol-Myers Squibb
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD96 antigen inhibitors; Natural killer cell stimulants; Natural killer T cell stimulants; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Solid tumours
  • Phase I Gastric cancer
  • Preclinical Breast cancer; Colorectal cancer

Most Recent Events

  • 21 Oct 2024 Bristol-Myers Squibb terminates phase I/II trial in Non-small cell lung cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Australia, Italy, Poland, Spain, USA (IV), as the business objectives of company have changed (NCT05543629)
  • 14 Jun 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease) in Poland (IV) (NCT05543629)
  • 05 Apr 2024 Preclinical trials in Colorectal cancer are ongoing in USA (IV) prior to April 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top